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We have carefully read the article written by Dr. Zhang 
et al. in which they reported your surgical experience in six 
patients with resectable epidermal growth factor receptor 
(EGFR) mutated non-small cell lung cancer (NSCLC) 
after gefitinib as neoadjuvant therapy (1). We know that the 
stage III of NSCLC comprises an important heterogeneous 
group of patients with big differences in terms of location 
and extension of the primary tumour as well as the 
mediastinal lymph nodes metastasis. The current tumor-
node-metastasis (TNM) (8th edition) shows us better the 
differences of this disease in terms of survival according 
to the stage of the disease at the moment of diagnosis (2). 
Currently, there are different therapeutic strategies used in 
the treatment of these tumours, including surgery followed 
by adjuvant chemotherapy (CT), induction CT and/or 
radiotherapy. For patients with unresectable disease, the 
indicated treatment is the concurrent chemoradiotherapy 
followed by durvalumab without any progression of the 
disease. The benefit of durvalumab was confirmed in 
the PACIFIC trial in which the overall survival (OS) was 
significantly longer in the group of treatment compared 
with the placebo group [hazard ratio (HR) for death, 0.68; 
95% confidence interval (CI), 0.470–0.997; P=0.0025]. 
The improvement in progression-free survival (PFS) was 
demonstrated also with a median of 17.2 vs. 5.6 months in 
the intervention group (HR, 0.51; 95% CI, 0.41–0.63) (3,4). 
This is the reason why it is very important to discuss each 
case and select the best treatment.
In several  studies have been demonstrated the 
improvement in survival of the patients treated with 
platinum-based adjuvant CT after a completely resected 
NSCLC. These results were confirmed in the LACE meta-
analysis which included more than 4,500 patients and 
showed a decrease in the risk of death of 5.4% at 5-year in 
patients treated with CT compared to the control group 
(HR, 0.89). However, it is necessary to remember that 
this benefit only was statistically significant in patients 
with stage II and IIIA of the disease (HR, 0.83) (5). The 
induction therapy is an other strategy evaluated also in this 
group of patients but the data is limited, compared with 
the adjuvant CT. However, comparative analyses seem 
to indicate that there are no differences in OS, although 
it can improve the results of surgery (6,7). The EGFR 
tyrosine kinase inhibitors (TKIs) has been evaluated also 
in induction therapy in patients potentially resectable of 
NSCLC, both in a molecularly selected population or not 
(8-10). In all cases the neoadjuvant therapy with TKIs has 
demonstrated good tolerability and safety but the results 
in terms of objective response rate (ORR) and survival are 
unequal. 
In his article, Dr. Zhang presents us a total of six cases of 
patients operated for primary lung adenocarcinoma after a 
period of 8 weeks of neoadjuvant treatment with gefitinib. 
Five of the patients had a stage IIIA of the disease and one 
case had a stage IIIB, according to the 7th edition of the 
TNM. 
However, we know that the stage IIIA includes a highly 
heterogeneous group of the disease and the complete 
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staging of the 6 cases was not described. For us, this is an 
important data to understand the impact of treatment on 
the down-staging of the tumour. In all cases, the status of 
EGFR was analysed previously to start the TKI therapy 
(3 cases of exon 19 deletion and 3 cases of exon 21 L858R 
mutation). The treatment tolerance, the type of surgery 
(lobectomy and mediastinal lymphadenectomy) and the 
postoperative pathologic staging have been described in 
only one isolated case.
We consider that despite being a series with a small 
number of cases, the scientific value is important and we 
want to contrast its results with the scientific evidence 
published so far. The CSLC-0702 (NCT00600587) is 
the first phase II study of biomarker-guided neoadjuvant 
treatment for patients with resectable NSCLC (stage 
IIIA-N2 confirmed) based on EGFR mutation status (8). 
In this clinical trial the patients were randomized according 
to the status of EGFR to receive neoadjuvant CT for three 
cycles (gemcitabine plus carboplatin) or erlotinib during 
42 days before the surgery. The primary endpoint was 
the ORR and the secondary were the PFS and the OS. 
The total number of patients included was 42 (twelve in 
every arm). The results show us an ORR of 41.7% in all 
population, being of 58.3% (7/12) in the EGFR mutant 
group (treated with TKI) versus 25% in the CT arm (P=0.18). 
The PFS was longer in the CT group (9 months; 95% CI, 
3.8–19.0 months) compared with the TKI group (6.9 months; 
95% CI, 3.1–15.0 months), there were no statistically 
significant differences (P=0.07). The OS was superior in the 
CT group with a median of 28.1 (95% CI, 0–66) vs. 14.5 (95% 
CI, 1–28) months for the erlotinib (P=0.201). In general, 
both treatments were well tolerated and any unexpected 
toxicities were observed. These results allow us to see that the 
neoadjuvant treatment with erlotinib setting tended to show 
an improved response but without any benefit in the PFS or 
in the OS. However, the small number of patients included 
in this trial can justify the absence of differences of efficacy 
between the treatment groups.
Another study, that has recently evaluated the role 
of neoadjuvant erlotinib in patients with stage IIIA-N2 
of  EGFR muta ted  NSCLC,  was  conducted  in  a 
single institution in China (Shanghai Chest Hospital), 
NCT01217619 (11). This is a prospective phase II study 
with a single arm, in which the patients received erlotinib 
150 mg per day for 56 days in the preoperative period. 
The primary endpoint was the radical resection rate and 
the secondary one included ORR, PFS, OS, complete 
pathologic response (CPR) rate, quality of life (QoL) 
and biomarkers. Nineteen EGFR mutated patients were 
enrolled and treated, 63% with an exon 19 deletion and 
47% with an exon 21 L858R mutation. After finishing the 
neoadjuvant treatment, 14 patients underwent surgery and 
the remaining 5 patients did not: 2 of them had progression 
of the disease, 2 more had severe adverse events and 
1 patient refused the intervention. The radical resection 
rate was 68.4% with a 21% rate of pathological down-
staging, without any CPR. The ORR was 42.1% with an 
average of 10.3 months of PFS in the group of the operated 
patients. Among all 19 patients who received neoadjuvant 
erlotinib, the median of PFS was 11.2 months and the OS 
was 51.6 months. In 8 of the operated patients the next-
generation sequencing revealed that 7 of them had a TP53 
gene mutation associated to an EGFR mutation. In these 
cases, the PFS was shorter (8 months) than the one in 
patients without this alteration. The authors concluded that 
the neoadjuvant erlotinib is a well-tolerated treatment and 
it improved the radical resection rate in this population. 
Finally, we want to comment the EMERGING-CTONG 
1103 study which is a multicenter, phase II, randomized 
controlled trial of erlotinib versus gemcitabine plus cisplatin 
as neoadjuvant/adjuvant therapy in patients with stage 
IIIA-N2 of NSCLC with EGFR mutations in exon 19 or 
21. In the TKI arm, the patients received erlotinib 150 mg 
per day as neoadjuvant therapy during 42 days and adjuvant 
therapy with the same dose up to 12 months, while in the 
CT arm were administrated 2 cycles of neoadjuvant CT and 
2 more cycles after the surgical intervention. The primary 
endpoint was the ORR and the secondary included CPR 
rate, PFS, OS, safety, and tolerability. Seventy-two patients 
were randomized (386 screened) and 71 were included in 
the safety analysis. The ORR for neoadjuvant treatment was 
54.1% in the erlotinib arm compared with the 34.3% in the 
CT group (odds ratio, 2.26; 95% CI, 0.87–5.84; P=0.092), 
without any CPR in either arm. The lymph node down-
staging was low in both groups, but higher in the erlotinib 
arm (10.8% vs. 2.9%). Only 3 patients achieved a major 
pathological response in the TKI group and none in the 
control group. The median of PFS was significantly longer 
in patients treated with erlotinib (21.5 months) compared 
with the CT arm (11.4 months), the HR was 0.39 (95% 
CI, 0.23–0.67; P=0.001). The median of the follow-up was 
32.5 months and no differences were observed in the OS 
between the two arms, 45.8 vs. 39.2 months in the TKI 
and CT group respectively (HR, 0.77; 95% CI, 0.41–1.45; 
P=0.417). Although the primary objective was not achieved, this 
study has been demonstrated a significantly improved in PFS in 
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patients treated with neoadjuvant/adjuvant erlotinib (12).
In the lasts years the impact of immunotherapy (IO) 
has been demonstrated in patients with advanced NSCLC, 
both in the first-line of treatment and in later lines (13-16). 
However, the anti-tumoral activity and the clinical 
benefit of IO in patients with EGFR mutated advanced 
NSCLC is lower than in wild-type population. Only 
the IMPOWER 150 study has demonstrated that the 
addition of IO to the scheme of CT (carboplatin/paclitaxel) 
plus bevacizumab improved the PFS and the ORR in 
EGFR mutated patients (17). Currently, the use of IO in 
monotherapy or combinated with CT is being evaluated 
in several clinical trials as a new induction treatment in 
patients with potentially resectable disease. In May 2018, 
Forde et al. published a study that evaluates the use of 
neoadjuvant nivolumab at a dose of 3 mg/kg every 2 weeks 
in a small cohort of patients with stages I−IIIA of NSCLC 
(NCT02259621) (18). From all 21 patients included 
(without any information about the status of EGFR), 
20 were subsequently operated. The major pathologic 
response (MPR) rate was 45% and the treatment was 
well tolerated. In the annual meeting of ASCO 2019, 
were presented de partial results of NADIM study 
(NCT03081689) which is a phase II, single-arm and open-
label multicenter study for patients with resectable stage 
IIIA-N2 NSCLC treated with the neoadjuvant combination 
of CT (carboplatin/paclitaxel) plus nivolumab every 
three weeks for 3 cycles. The primary endpoint in this 
study was the PFS at 24 months and the data of efficacy 
is explored using objective pathologic response criteria. 
With 30 patients included and 13 underwent surgery, 
the tolerability of the treatment was excellent without 
any severe adverse events. The CPR rate was 69.2% 
(95% CI, 38.6–90.9%) plus 2 cases with a MPR, defined 
as <10% viable tumour cells in the resection specimen. 
Considering both types of response (CPR and MPR), the 
ORR was 84.6% (95% CI, 54.6–98.1%). These results 
are very important in the development of new therapeutic 
strategies in the management of the patients with locally 
advanced NSCLC (19). The update data of this study with 
46 patients included, presented in IASLC 2019 in 
Barcelona, confirmed the high rate of objective pathological 
responses in these patients. Only one case has been reported 
with a known EGFR mutation that reached a higher 
response but subsequently relapsed in the central nervous 
system. Another study, similar to the previous one, but with 
fewer patients (14 cases) and using 4 cycles of neoadjuvant 
CT (carboplatin/nab-paclitaxel) plus atezolizumab, showed 
important pathological responses, but more discrete than 
the NADIM study (20).
With all these results, we consider that it is important 
to continue the research in order to clarify the impact of 
neoadjuvant therapy with TKI in EGFR mutated locally 
advanced lung cancer. Despite the good results of the 
use of TKIs in the first-line of treatment, they can not 
be extrapolated to preoperative management of these 
tumours without having more consistent data. There are 
serious doubts about the ideal period of time necessary 
for neoadjuvant treatment with TKIs and whether this 
should be followed by adjuvant therapy or not. It is 
necessary that new studies will be designed to evaluate this 
therapeutic strategy, including more extensive molecular 
data (sensitizing and resistance mutations, common and 
uncommon mutations, coexistence of diverse mutations and 
the tumour mutational burden). Another question which 
arises is whether the benefit of the neoadjuvant treatment, 
combining CT plus IO, can have the same impact in EGFR 
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